FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W85928981> ?p ?o ?g. }

• W85928981 endingPage "P77" @default.
• W85928981 startingPage "P77" @default.
• W85928981 abstract "This article was originally published online on 23 April 2013 The inflammasome is a novel protein complex that stimulates caspase-1 activation to promote the processing and secretion of IL-1β, a pro-inflammatory cytokine, which is among the most biologically important inflammatory mediators in allergic airway diseases. Among the various types of inflammasomes, Cryopyrin/NALP3 has been suggested to be involved in sensing sterile stress response, extracellular ATP, danger-associated molecular patterns (DAMPs), and crystals. Recently inappropriate NALP3 inflammasome activity has been reported in various allergic airway diseases including asthma. Therefore, inhibitors of the NALP3 inflammasome offer considerable therapeutic promise. Recently Omega-3 fatty acid derivates termed resolvins have shown to alter the effects of pro-inflammatory cytokine storm seen in inflammatory diseases. However the ability of resolvins to modulate the effects of inflammasome activation has not been studied. We investigated whether resolvin treatment inhibits inflammasome activation and regulates the functional effects of inflammasome mediated by IL-1β secretion. In our study the inflammasome was activated by ATP and H2O2 (known nflammasome activators in acute lung injury) in the absence or presence of D series resolvins, resolvin D1 and resolvin D2. Inflammasome activation was assessed by analyzing IL-1β release (end product of inflammasome activation) and caspase-1 cleavage (indicator of inflammasome activation) in THP-1 cells. Further inflammasome was activated in the presence or absence of resolvin in THP-1 cells, and supernatants from these cells were added to A549 cells and human primary small airway epithelial cells (HPSAEC) to study inflammasome mediated functional effects. Our results indicate that resolvin treatment ameliorates inflammasome activation as indicated by decreased caspase-1 activity and IL-1β release. In addition resolvin treatment inhibits inflammasome mediated epithelial cell activation as indicated by suppressed IL-8 release and decreased and ICAM expression. These novel findings suggest that resolvins can be used to modulate the inflammasome activity as well as blunt the effects of the IL-1β mediated cytokine storm stemming from inflammasome activation. These results may offer a therapeutic approach to airway diseases such as asthma, where ungoverned pro-inflammatory cytokine secretion exacerbates the disease pathology." @default.
• W85928981 created "2016-06-24" @default.
• W85928981 creator A5046258351 @default.
• W85928981 creator A5067663273 @default.
• W85928981 date "2013-01-01" @default.
• W85928981 modified "2023-10-17" @default.
• W85928981 title "Mechanisims of asthma and allergic disease – 1081. Resolvin inhibits the cryopyrin/nalp3 inflammasome" @default.
• W85928981 doi "https://doi.org/10.1186/1939-4551-6-s1-p77" @default.
• W85928981 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3643793" @default.
• W85928981 hasPublicationYear "2013" @default.
• W85928981 type Work @default.
• W85928981 sameAs 85928981 @default.
• W85928981 citedByCount "0" @default.
• W85928981 crossrefType "journal-article" @default.
• W85928981 hasAuthorship W85928981A5046258351 @default.
• W85928981 hasAuthorship W85928981A5067663273 @default.
• W85928981 hasBestOaLocation W859289811 @default.
• W85928981 hasConcept C126322002 @default.
• W85928981 hasConcept C139964883 @default.
• W85928981 hasConcept C162157009 @default.
• W85928981 hasConcept C187831198 @default.
• W85928981 hasConcept C203014093 @default.
• W85928981 hasConcept C2776914184 @default.
• W85928981 hasConcept C2777209026 @default.
• W85928981 hasConcept C2778690821 @default.
• W85928981 hasConcept C49039625 @default.
• W85928981 hasConcept C68239362 @default.
• W85928981 hasConcept C71924100 @default.
• W85928981 hasConcept C86803240 @default.
• W85928981 hasConcept C95444343 @default.
• W85928981 hasConceptScore W85928981C126322002 @default.
• W85928981 hasConceptScore W85928981C139964883 @default.
• W85928981 hasConceptScore W85928981C162157009 @default.
• W85928981 hasConceptScore W85928981C187831198 @default.
• W85928981 hasConceptScore W85928981C203014093 @default.
• W85928981 hasConceptScore W85928981C2776914184 @default.
• W85928981 hasConceptScore W85928981C2777209026 @default.
• W85928981 hasConceptScore W85928981C2778690821 @default.
• W85928981 hasConceptScore W85928981C49039625 @default.
• W85928981 hasConceptScore W85928981C68239362 @default.
• W85928981 hasConceptScore W85928981C71924100 @default.
• W85928981 hasConceptScore W85928981C86803240 @default.
• W85928981 hasConceptScore W85928981C95444343 @default.
• W85928981 hasLocation W859289811 @default.
• W85928981 hasLocation W859289812 @default.
• W85928981 hasLocation W859289813 @default.
• W85928981 hasOpenAccess W85928981 @default.
• W85928981 hasPrimaryLocation W859289811 @default.
• W85928981 hasRelatedWork W1968182403 @default.
• W85928981 hasRelatedWork W1975563740 @default.
• W85928981 hasRelatedWork W1978274182 @default.
• W85928981 hasRelatedWork W2019988013 @default.
• W85928981 hasRelatedWork W2090859543 @default.
• W85928981 hasRelatedWork W2134735862 @default.
• W85928981 hasRelatedWork W2155177346 @default.
• W85928981 hasRelatedWork W3144262249 @default.
• W85928981 hasRelatedWork W4210272237 @default.
• W85928981 hasRelatedWork W85928981 @default.
• W85928981 hasVolume "6" @default.
• W85928981 isParatext "false" @default.
• W85928981 isRetracted "false" @default.
• W85928981 magId "85928981" @default.
• W85928981 workType "article" @default.